Business description
After the merger with Cytos Biotechnology Ltd in 2016 the Kuros Biosciences Ltd is developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. Kuros Biosciences Ltd is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands.
Management board & Supervisory board
| CEO |
| Chris Fair |
| Management board |
| Daniel Geiger, Dr. Joost de Bruijn, Sjoerd Musters, Dr. Philippe Saudan, Dr. Florence Barrére de Groot, John Griffin, Dr. Katherine Sage, Marcel Borger, Nikki Coleman, G. Joseph Ross |
| Supervisory board |
| Prof. Dr. Clemens van Blitterswijk, Prof. Joost de Bruijn, Oliver Walker, Alber Arp, Chris Fair |
Company data
| Name: |
Kuros Biosciences AG |
| Address: |
Wagistraße 25,CH-8952 Schlieren |
| Phone: |
+41-44-733-4747 |
| Fax: |
+41-44-733-4740 |
| E-mail: |
info@kurosbio.com
|
| Internet: |
www.kuros.ch |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
31/12 |
| Free Float: |
49.30% |
| IPO date: |
- |
